Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated
by Zacks Equity Research
Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.
Integra (IART) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.
Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q3.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.
IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
ABIOMED's (ABMD) international Impella revenues improved in Q2.
CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3
Cerner (CERN) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Cerner's (CERN) third-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in margins.
PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.
QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up
by Zacks Equity Research
QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Boston Scientific (BSX) Q3 Earnings Top, Margins Decline
by Zacks Equity Research
Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.
Top Analyst Reports for Thermo Fisher, SAP & Bristol-Myers
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific (TMO), SAP SE (SAP) and Bristol-Myers Squibb (BMY).
LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service
by Zacks Equity Research
Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.
Stock Market News for Oct 22, 2020
by Zacks Equity Research
Benchmarks closed slightly lower on Wednesday as investors continued to look for signs of progress on a new fiscal stimulus deal.
Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell
by Mark Vickery
Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales
by Zacks Equity Research
Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.
Align's (ALGN) ClinCheck Suite Now Commercially Available
by Zacks Equity Research
Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.
Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 28.83% and 10.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: DKS, ATVI, TMO, FBHS and TSM
by Zacks Equity Research
Zacks.com featured highlights include: DKS, ATVI, TMO, FBHS and TSM
Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View
by Zacks Equity Research
Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.
Baxter Supports Findings of Ongoing COVID-19 Nutrition Study
by Zacks Equity Research
The study, supported by Baxter (BAX) through an investigator-initiated grant, is the first analysis of longitudinal REE in critically ill, mechanically-ventilated COVID-19 patients.
Here's Why You Should Invest in AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
LHC Group (LHCG) and CHRISTUS Health Extend JV Partnership
by Zacks Equity Research
LHC Group (LHCG) and CHRISTUS Health expand their partnership to boost home health services and hospice care.